A61K 39/165
Mumps or measles virus
A61K39/165 (Mumps or measles virus) appears on 128 US grants and 161 published applications in this corpus.
Search patents in A61K- Granted patents
- 128
- Published applications
- 161
- Assignees
- 121
- Inventors
- 345
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 1 | 0 |
| 1979 | 1 | 0 |
| 1980 | 1 | 0 |
| 1981 | 1 | 0 |
| 1982 | 2 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 3 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 2 | 0 |
| 1999 | 2 | 0 |
| 2000 | 2 | 0 |
| 2001 | 6 | 0 |
| 2002 | 2 | 6 |
| 2003 | 4 | 8 |
| 2004 | 1 | 2 |
| 2005 | 1 | 5 |
| 2006 | 2 | 1 |
| 2007 | 1 | 4 |
| 2008 | 4 | 2 |
| 2009 | 0 | 4 |
| 2010 | 2 | 4 |
| 2011 | 1 | 9 |
| 2012 | 3 | 6 |
| 2013 | 0 | 4 |
| 2014 | 4 | 11 |
| 2015 | 5 | 8 |
| 2016 | 4 | 10 |
| 2017 | 8 | 11 |
| 2018 | 8 | 15 |
| 2019 | 11 | 6 |
| 2020 | 13 | 10 |
| 2021 | 10 | 9 |
| 2022 | 5 | 6 |
| 2023 | 3 | 6 |
| 2024 | 7 | 3 |
| 2025 | 2 | 4 |
| 2026 | 3 | 7 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Measles virus vaccine expressing SARS-CoV-2 protein(s)16 Jun 2026US 12,653,881 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Mumps and measles virus immunogens and their use26 May 2026US 12,636,360 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Transient expression of biologic materials17 Mar 2026US 12,576,041 B1
- F-genotype mumps virus attenuated strain and construction method therefor and application thereof2 Dec 2025US 12,486,497 B2Beijing Cell-Fusion Biotechnology Co., Ltd.
- Compositions and methods for stabilization of active agents22 Apr 2025US 12,280,101 B2Trustees of Tufts College
- Inhaled adenovirus vector vaccine, preparation method therefor and use thereof8 Oct 2026US 2026/0306605 A1Cansino Biologics Inc.
- Nucleic acid-lipid nanoparticle composition, and lyophilized preparation thereof, preparation method therefor and use thereof1 Oct 2026US 2026/0294829 A1Cansino Biologics Inc.
- Mumps and measles virus immunogens and their use20 Aug 2026US 2026/0240984 A1The United States of America, as represented by the Secretary, Department of Health and Human Ser.
- Adjuvant and transmucosal vaccine2 Jul 2026US 2026/0183384 A1Juntendo Educational Foundation
- Vaccine antigens and use thereof29 Jan 2026US 2026/0027197 A1Morehouse School of Medicine
Most cited
By later US patents
- Immunotherapy of epithelial tumors using intralesional injection of antigens that induce a delayed type hypersensitivity reaction188US 6,350,451 B1Board of Trustees of the University of Arkansas · 2002
- Modified Morbillivirus V proteins65US 6,664,066 B2Wyeth Holdings Corporation · 2003
- Transcutaneous delivery of therapeutic agents49US 8,728,491 B2Alba Therapeutics Corporation · 2014
- cDNA corresponding to the antigenome of nonsegmented negative stranded RNA viruses and process for the production of such viruses40US 7,993,924 B2Crucell Switzerland AG · 2011
- Production of viruses in tissue culture without use of serum39US 4,072,565 AThe Dow Chemical Company · 1978